Skip to main content

Table 2 Burden of ICC attributable to HPV 16/18 and HPV 31/33/45/52/58 in 2012, projected to 2025; by region

From: Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease

Region HPV RC (%) Attributable new cases (N)
16/18 31/33/45/ 52/58 Year 2012 Year 2025
16/18 31/33/45/ 52/58 16/18 31/33/45/52/58
World 70.8 18.6 391,016 102,172 444,167 116,061
Africa 70.3 16.7 60,925 14,438 80,556 19,090
Asia 71.7 19.8 232,046 63,986 259,130 71,454
Eastern Asia 68.9 22.3 95,505 30,869 100,950 32,629
Western/Central Asia 77.5 14.5 145,101 27,073 171,333 31,967
Latin-America 68.3 19.8 48,777 14,142 54,973 15,938
South America 69.4 19.6 34,632 9,799 38,783 10,973
Central America 64.4 20.2 13,602 4,264 15,522 4,866
North America 78.7 16.6 9,913 2,094 10,913 2,305
Europe 72.8 16.2 39,880 8,867 39,924 8,877
Oceania 78.5 8.8 1,346 152 1,587 179
  1. * We assume that almost all cervical cancer cases are caused by HPV infection, and thus almost 100% of cervical cancer cases are attributable to HPV infection.
  2. "ICC": Invasive cervical cancer; “RC”: Relative Contribution; “N”: Number of new cases diagnosed of cervical cancer each year.
  3. Estimated number of new ICC cases is based on GLOBOCAN 2008 estimates and World Population Prospects (2010 revision). Impact of vaccination has not been taken into account for the calculations of 2025 projections.
  4. Specific information on HPV 6 and 11 is not included due to low relative contribution of these types.